Patents Assigned to Eyegate Pharma, S.A.
  • Patent number: 9238131
    Abstract: The invention relates to a device of ocular iontophoresis for delivering active substances, comprising a reservoir having an outer wall and a hollow body at least partly delimited by the outer wall, wherein the hollow body is capable of receiving an electrical conductive medium and active substances contained in the medium and has an outlet defining a surface, so-called “application surface”, intended to received a determine part of an eyeball surface, the application surface being at least partly limited by an outer line concave towards the optical axis of the eyeball, wherein the outer wall extends from the outer line with a global outwardly with respect to the said optical axis.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: January 19, 2016
    Assignee: EYEGATE PHARMA S.A.S.
    Inventor: Pierre Roy
  • Patent number: 9192512
    Abstract: The invention concerns a device for ocular application of an active principle (1) comprising a main electrode (2) including an insulating layer, an adhesive layer designed to bind the insulating layer to a conductive layer, characterized in that the main electrode comprises a zone (21, 22) designed to be urged into contact with an eyelid.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: November 24, 2015
    Assignee: EYEGATE PHARMA S.A.S.
    Inventors: Francine Behar-Cohen, Pierre Roy
  • Patent number: 8771256
    Abstract: The invention concerns a device for ocular application of an active principle (1) comprising a main electrode (2) including an insulating layer, an adhesive layer designed to bind the insulating layer to a conductive layer, characterized in that the main electrode comprises a zone (21, 22) designed to be urged into contact with an eyelid.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: July 8, 2014
    Assignee: Eyegate Pharma S.A.
    Inventors: Francine Behar-Cohen, Pierre Roy
  • Patent number: 8611994
    Abstract: The invention provides an ocular iontophoresis device for delivering medication, the device comprising a medication reservoir suitable for being positioned on the eye, at least one medication in solution in the reservoir, an active electrode disposed in the reservoir, and a passive electrode, the device including at least one medication dissolved in non-saline water, the said solution having a lying in the range 6.5 to 8.5, the medication having a pKa lying in the range about 5.5 to about 9.5 and includes an active principle which is associated with an additive, such as a dendrimer, a polymer, a nanoparticle, a microsphere, a liposome, or an emulsion, and having an ionic form of valency greater than or equal to 1.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: December 17, 2013
    Assignee: EyeGate Pharma S.A.S.
    Inventor: Pierre Roy
  • Patent number: 8452391
    Abstract: The invention relates to a device of ocular iontophoresis for delivering active substances, comprising a reservoir having an outer wall and a hollow body at least partly delimited by the outer wall, wherein the hollow body is capable of receiving an electrical conductive medium and active substances contained in the medium and has an outlet defining a surface, so-called “application surface”, intended to received a determine part of an eyeball surface, the application surface being at least partly limited by an outer line concave towards the optical axis of the eyeball, wherein the outer wall extends from the outer line with a global outwardly with respect to the said optical axis.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: May 28, 2013
    Assignee: EyeGate Pharma S.A.S.
    Inventor: Pierre Roy
  • Patent number: 8306613
    Abstract: The invention provides an ocular iontophoresis device for delivering medication, the device comprising a medication reservoir suitable for being positioned on the eye, at least one medication in solution in the reservoir, an active electrode disposed in the reservoir, and a passive electrode, the device including at least one medication dissolved in non-saline water, the said solution having a pH lying in the range 6.5 to 8.5, the medication having a pKa lying in the range about 5.5 to about 9.5 and includes an active principle which is associated with an additive, such as a dendrimer, a polymer, a nanoparticle, a microsphere, a liposome, or an emulsion, and having an ionic form of valency greater than or equal to 1.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: November 6, 2012
    Assignee: EyeGate Pharma S.A.S.
    Inventor: Pierre Roy
  • Publication number: 20120089077
    Abstract: The invention relates to a device of ocular iontophoresis for delivering active substances, comprising a reservoir having an outer wall and a hollow body at least partly delimited by the outer wall, wherein the hollow body is capable of receiving an electrical conductive medium and active substances contained in the medium and has an outlet defining a surface, so-called “application surface”, intended to received a determine part of an eyeball surface, the application surface being at least partly limited by an outer line concave towards the optical axis of the eyeball, wherein the outer wall extends from the outer line with a global outwardly with respect to the said optical axis.
    Type: Application
    Filed: December 15, 2011
    Publication date: April 12, 2012
    Applicant: EYEGATE PHARMA, S.A.S.
    Inventor: Pierre ROY
  • Patent number: 8099162
    Abstract: The invention relates to a device of ocular iontophoresis for delivering active substances, comprising a reservoir having an outer wall and a hollow body at least partly delimited by the outer wall, wherein the hollow body is capable of receiving an electrical conductive medium and active substances contained in the medium and has an outlet defining a surface, so-called “application surface”, intended to receive a determine part of an eyeball surface, the application surface being at least partly limited by an outer line concave towards the optical axis of the eyeball, wherein the outer wall extends from the outer line with a global outwardly with respect to the said optical axis.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: January 17, 2012
    Assignee: EyeGate Pharma, S.A.S.
    Inventor: Pierre Roy
  • Publication number: 20110306923
    Abstract: The invention provides an ocular iontophoresis device for delivering medication, the device comprising a medication reservoir suitable for being positioned on the eye, at least one medication in solution in the reservoir, an active electrode disposed in the reservoir, and a passive electrode, the device including at least one medication dissolved in non-saline water, the said solution having a pH lying in the range 6.5 to 8.5, the medication having a pKa lying in the range about 5.5 to about 9.5 and includes an active principle which is associated with an additive, such as a dendrimer, a polymer, a nanoparticle, a microsphere, a liposome, or an emulsion, and having an ionic form of valency greater than or equal to 1.
    Type: Application
    Filed: August 25, 2011
    Publication date: December 15, 2011
    Applicant: EYEGATE PHARMA, S.A.S.
    Inventor: Pierre Roy
  • Patent number: 7937142
    Abstract: The invention provides an ocular iontophoresis device for delivering medication, the device comprising a medication reservoir suitable for being positioned on the eye, at least one medication in solution in the reservoir, an active electrode disposed in the reservoir, and a passive electrode, the device including at least one medication dissolved in non-saline water, the said solution having a pH lying in the range 6.5 to 8.5, the medication having a pKa lying in the range about 5.5 to about 9.5 and includes an active principle which is associated with an additive, such as a dendrimer, a polymer, a nanoparticle, a microsphere, a liposome, or an emulsion, and having an ionic form of valency greater than or equal to 1.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: May 3, 2011
    Assignee: EyeGate Pharma S.A.S.
    Inventor: Pierre Roy
  • Patent number: 7848800
    Abstract: The invention concerns a device for ocular application of an active principle (1) comprising a main electrode (2) including an insulating layer, an adhesive layer designed to bind the insulating layer to a conductive layer, characterized in that the main electrode comprises a zone (21, 22) designed to be urged into contact with an eyelid.
    Type: Grant
    Filed: October 11, 2002
    Date of Patent: December 7, 2010
    Assignee: Eyegate Pharma S.A.S.
    Inventors: Francine Behar-Cohen, Pierre Roy
  • Patent number: 7771403
    Abstract: The feed connector (270) capable of interacting with a device for delivering active principles comprising a reservoir delimited by at least two lateral walls of substantially cylindrical shape and extending opposite one another, is characterized in that it includes means (202, 203, 204, 205) for dispensing active principles into the reservoir that are arranged such that said reservoir is filled substantially uniformly between the two lateral walls.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: August 10, 2010
    Assignee: Eyegate Pharma S.A.
    Inventor: Pierre Roy
  • Patent number: 7684857
    Abstract: The invention concerns a device for ocular delivery of an active principle by peroperative intraocular iontophoresis or electroporation comprising a reservoir (7) for receiving a solution comprising the active principle, means for diffusing (8, 6) the active principle connected to the reservoir, means for injecting (4) the solution into the reservoir, and means (5) for exerting suction of the content of the reservoir during an injection of the solution therein by the injection means.
    Type: Grant
    Filed: October 11, 2002
    Date of Patent: March 23, 2010
    Assignee: Eyegate Pharma S.A.S.
    Inventors: Francine Behar, Pierre Roy
  • Patent number: 7628781
    Abstract: The invention relates to a connector assembly (10) for the transfer of fluids, particularly fluids comprising an active agent from a reservoir to a medical device for dosage, comprising: a first connector element (20), pertaining to the reservoir with first fixing means (23), a second connector element (10), pertaining to the medical dosage device with second fixing means (12), cooperating with the first fixing means to give an irreversible connection between the two elements. The first and second elements are embodied such as to cooperate with other by clipping on a single translational movement of a connector element relative to the other to produce the irreversible connection, characterized in that at least one of the connection elements is embodied with means to render the same breakable.
    Type: Grant
    Filed: March 7, 2003
    Date of Patent: December 8, 2009
    Assignee: Eyegate Pharma S.A.S.
    Inventors: Pierre Roy, Alain Kleinsinger
  • Patent number: 7548778
    Abstract: The invention provides an ocular iontophoresis device for delivering medication, the device comprising a medication reservoir suitable for being positioned on the eye, at least one medication in solution in the reservoir, an active electrode disposed in the reservoir, and a passive electrode, the device including at least one medication dissolved in non-saline water, the said solution having a pH lying in the range 6.5 to 8.5, the medication having a pKa lying in the range about 5.5 to about 9.5 and includes an active principle which is associated with an additive, such as a dendrimer, a polymer, a nanoparticle, a microsphere, a liposome, or an emulsion, and having an ionic form of valency greater than or equal to 1.
    Type: Grant
    Filed: January 8, 2007
    Date of Patent: June 16, 2009
    Assignee: Eyegate Pharma S.A.S.
    Inventor: Pierre Roy
  • Patent number: 7164943
    Abstract: The invention provides an ocular iontophoresis device for delivering medication, the device comprising a medication reservoir suitable for being positioned on the eye, at least one medication in solution in the reservoir, an active electrode disposed in the reservoir, and a passive electrode, the device including at least one medication dissolved in non-saline water, the said solution having a pH lying in the range 6.5 to 8.5, the medication having a pKa lying in the range about 5.5 to about 9.5 and includes an active principle which is associated with an additive, such as a dendrimer, a polymer, a nanoparticle, a microsphere, a liposome, or an emulsion, and having an ionic form of valency greater than or equal to 1.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: January 16, 2007
    Assignee: Eyegate Pharma, S.A.
    Inventor: Pierre Roy